Novel Therapeutic Strategy for Melanoma Based on Albendazole and the CDK4/6 Inhibitor Palbociclib

The authors demonstrated that albendazole, an FDA-approved broad-spectrum antiparasitic agent, significantly inhibited the proliferation of melanoma cells in vitro and in vivo.